Hippo-YAP1 Is a Prognosis Marker and Potentially Targetable Pathway in Advanced Gallbladder Cancer

Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma

(2019) Yoshimasa Saito et al.   Cell Reports

Cancer modeling meets human organoid technology

(2019) David Tuveson et al.   SCIENCE

Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma

(2019) Jacopo Gavini et al.   Cell Death & Disease

Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway

(2018) Liang Dong et al.   International Journal of Medical Sciences

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

(2018) Georgios Vlachogiannis et al.   SCIENCE

Verteporfin enhances the sensitivity of LOVO/TAX cells to taxol via YAP inhibition

(2018) Ganggang Shi et al.   Experimental and Therapeutic Medicine

Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors

(2018) Isabel Romero-Calvo et al.   MOLECULAR CANCER RESEARCH

The Hippo pathway effector TAZ induces TEAD-dependent liver inflammation and tumors

(2018) Thijs J. Hagenbeek et al.   Science Signaling

Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

(2018) J. Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Mst1 regulates non-small cell lung cancer A549 cell apoptosis by inducing mitochondrial damage via ROCK1/F‑actin pathways

(2018) Weiqiang Zhang et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Altered Expression of Hippo Signaling Pathway Molecules in Intrahepatic Cholangiocarcinoma

(2017) Keishi Sugimachi et al.   ONCOLOGY

Mammalian sterile 20‑like kinase 1 expression and its prognostic significance in patients with breast cancer

(2017) Xiao‑Yan Lin et al.   Oncology Letters

Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells

(2017) Venkata Ramesh Dasari et al.   Oncotarget

Analysis of prognostic factors for survival after surgery for gallbladder cancer based on a Bayesian network

(2017) Zhi-qiang Cai et al.   Scientific Reports

The inflammatory inception of gallbladder cancer

(2016) Jaime A. Espinoza et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

YAP/TAZ at the Roots of Cancer

(2016) Francesca Zanconato et al.   CANCER CELL

TAZ regulates cell proliferation and sensitivity to vitamin D3 in intrahepatic cholangiocarcinoma

(2016) Heng Xiao et al.   CANCER LETTERS

Verteporfin can Reverse the Paclitaxel Resistance Induced by YAP Over-Expression in HCT-8/T Cells without Photoactivation through Inhibiting YAP Expression

(2016) Wang Pan et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

R‐spondin 1 and noggin facilitate expansion of resident stem cells from non‐damaged gallbladders

(2016) Natalia Lugli et al.   EMBO REPORTS

Verteporfin, a suppressor of YAP–TEAD complex, presents promising antitumor properties on ovarian cancer

(2016) Zhengyu Li et al.   OncoTargets and Therapy

YAP promotes erlotinib resistance in human non-small cell lung cancer cells

(2016) Ping-Chih Hsu et al.   Oncotarget

Tumor Location Is a Strong Predictor of Tumor Progression and Survival in T2 Gallbladder Cancer

(2015) Junichi Shindoh et al.   ANNALS OF SURGERY

TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinoma

(2015) Heng Xiao et al.   CANCER SCIENCE

Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor

(2015) A. Sebio et al.   CLINICAL CANCER RESEARCH

Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients

(2015) Jaime A Espinoza et al.   HISTOPATHOLOGY

Functional and Clinical Evidence That TAZ is a Candidate Oncogene in Hepatocellular Carcinoma

(2015) Yan Guo et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

A gp130–Src–YAP module links inflammation to epithelial regeneration

(2015) Koji Taniguchi et al.   NATURE

Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1

(2015) Huabing Zhang et al.   Science Signaling

Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice

(2015) Helga Weber et al.   Oncotarget

Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1

(2015) Huabing Zhang et al.   Science Signaling

Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer

(2014) M T Huggett et al.   BRITISH JOURNAL OF CANCER

Yes-associated protein 1 (YAP1) promotes human gallbladder tumor growth via activation of the AXL/MAPK pathway

(2014) Maolan Li et al.   CANCER LETTERS

The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation

(2014) Katarzyna Brodowska et al.   EXPERIMENTAL EYE RESEARCH

YAP activation is an early event and a potential therapeutic target in liver cancer development

(2014) Andrea Perra et al.   JOURNAL OF HEPATOLOGY

Lymph node status after resection for gallbladder adenocarcinoma: Prognostic implications of different nodal staging/scoring systems

(2014) Neda Amini et al.   JOURNAL OF SURGICAL ONCOLOGY

Prognostic significance of mammalian sterile 20-like kinase 1 in breast cancer

(2013) Xiaoyan Lin et al.   TUMOR BIOLOGY

Bile Acids Activate YAP to Promote Liver Carcinogenesis

(2013) Sayeepriyadarshini Anakk et al.   Cell Reports

The Autophagy Inhibitor Verteporfin Moderately Enhances the Antitumor Activity of Gemcitabine in a Pancreatic Ductal Adenocarcinoma Model

(2013) Elizabeth Donohue et al.   Journal of Cancer

Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP

(2012) Y. Liu-Chittenden et al.   GENES & DEVELOPMENT

Expression of Yes-associated protein modulates Survivin expression in primary liver malignancies

(2012) Haibo Bai et al.   HUMAN PATHOLOGY

Yes-Associated Protein 1 Exhibits Oncogenic Property in Gastric Cancer and Its Nuclear Accumulation Associates with Poor Prognosis

(2011) W. Kang et al.   CLINICAL CANCER RESEARCH

YAP is a candidate oncogene for esophageal squamous cell carcinoma

(2010) Tomoki Muramatsu et al.   CARCINOGENESIS

Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma

(2009) Michelle Z. Xu et al.   CANCER